Marketing & Promotion of Off-Label Uses of Repetitive TMS Treatment (rTMS)
2026-04-07 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Lindsay Oberman, PhD
This talk will review the Pro’s and Cons of off-label use of TMS. Dr. Oberman will then discuss the FDA clearance process and what indications are considered “off-label”. Finally, she will discuss the legal and ethical considerations for marketing and promoting off-label uses of TMS.
Key learning objectives include:

Gain awareness of what indications are "on label" versus "off label."
Gain awareness of federal regulations regarding marketing and promotion of FDA cleared devices.
Gain understanding of ethical considerations regarding marketing and use of rTMS off-label.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, April 10, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - April 7, 2026 at 8:00pm ET | 5:00pm PT
UK- April 8, 2026 at 1:00am BST
Australia- April 8, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Lindsay Oberman, PhD
Dr. Lindsay Oberman received her PhD from UCSD in Experimental Psychology in 2007. Since that time, she has published over 80 peer-reviewed articles. She has gained international attention for pioneering the use of Repetitive Transcranial Magnetic Stimulation (rTMS) in complex neurodevelopmental and neuropsychiatric disorders including autism, mood disorders, and traumatic brain injury. Dr. Oberman’s research involves the use of an experimental therapeutics approach applying neuroimaging and neurophysiological measures to identify dysfunctional neural circuitry associated with specific transdiagnostic behavioral domains such as mood regulation, sensory processing, social cognition, and executive functioning across disorders. In doing so, she is able to develop novel individualized rTMS treatment protocols that are informed by functional brain network organization. She is currently a Staff Scientist and Directs the Developmental Clinical Neurophysiology and Neurostimulation Research Program within the National Institute of Mental Health Intramural Research Program.

Combined Occipital and Trigeminal Afferent Stimulation for Depression: Findings from the Randomized Controlled Trial and the New ProLiv Home-Use Neuromodulation Device
2026-05-05 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Linda Carpenter, MD
Earlier this year, the FDA approved a novel home-use device for treatment of major depressive disorder in patients who have not responded to antidepressant medication. Available only with a prescription, Proliv™Rx is a wearable, at-home neurostimulation headset that uses non-invasive electrical pulses to stimulate the occipital and trigeminal nerves through surface electrodes.
Dr. Carpenter was the lead Principal Investigator for the large randomized controlled trial that generated efficacy and safety data for this device. She will present the data and describe how the ProLiv device will be used in future clinical practice.
Key learning objectives include:

Evaluate the clinical trial data supporting efficacy and safety of a new home-use device for treatment of Major Depressive Disorder (MDD).
Describe external combined occipital and trigeminal stimulation as a novel mechanism of action in the field of therapeutic neuromodulation.
Discuss how the ProLiv Rx device is incorporated into clinical care as an adjunct therapy for MDD.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, May 8, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - May 5, 2026 at 8:00pm ET | 5:00pm PT
UK- May 6, 2026 at 1:00am BST
Australia- May 6, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Linda Carpenter, MD
Dr. Carpenter has had nearly three decades of externally funded research focused on understanding biomarkers of early life stress and developing new treatments. She has expertise in clinical trials research involving pharmacotherapy and device-based neuromodulation treatments and has been PI on multiple industry- and NIH-funded randomized clinical trials, evaluating the safety and efficacy of both drug- and device-based therapies for depression and anxiety disorders. She has also conducted studies examining various mechanisms of therapeutic action and biomarkers of risk for psychiatric disorders.
For the past two decades, Dr. Carpenter's primary research focus has included therapeutic brain stimulation, and she has led numerous studies examining the efficacy, safety, and mechanisms of VNS, DBS, tDCS, TMS, and other neuromodulation devices in clinical populations.
Dr. Carpenter recently led the multi-center investigation of Proliv, a novel, FDA-cleared home-use device that delivers electrical trigeminal/occipital nerve stimulation for depression, and she is lead PI for a trial that uses fMRI-EEG-based neurofeedback for self-neuromodulation of a targeted depression circuit.
For the past 5 years Dr. Carpenter has also been developing methods for sustaining TMS antidepressant response over time with maintenance treatment and ecological momentary assessment.
Dr. Carpenter is the current Director of the CTMSS’s PULSES training course, and she serves on multiple other CTMSS committees.

PULSES Boston
2026-06-03 - 2026-06-04
Course Overview
This in-depth training course offers a Certificate of Completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians, engineers, and researchers, along with special guests. Attendees will receive current, historical, and practical knowledge for treating patients with TMS based on the best available evidence.
The Program Includes:

A review of the clinical studies that serve as the foundation for treatment of TMS for depression, as well as clinically applicable research and current important studies.
Four lectures on the practical administration of TMS for patients, including practice setup to patient dosing, scheduling, and management.
A review of protocols for TMS: high frequency, theta-burst, low frequency, bilateral, alternative brain targets, rescue treatment, and maintenance treatment.
A revised lecture on TMS risks and their prevention and management, including seizure protocol review.
Hands-on training on coil location placement & motor threshold determination with multiple TMS devices.
A review of promising indications beyond depression, including, obsessive compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, anxiety, and pain.
An extended Q&A Panel with all PULSES faculty and special guests.

MORE DETAILS COMING SOON... Sign up for updates on when CTMSS opens PULSES registration...

Pain Academy Boston
2026-06-04

CTMSS 14th Annual Meeting
2026-06-04 - 2026-06-06

Clinical Outcomes Comparing MST and ECT in Patients with Depression
2026-07-07 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Daniel M. Blumberger, MD, MSc, FRCPC, FCTMSS
This presentation will present data from a large confirmatory efficacy trial of Magnetic Seizure Therapy in unipolar Depression and a smaller trial in patients with Bipolar Depression.
This treatment utilizes transcranial magnetic stimulation to induce a brief seizure with the hope of inducing similar clinical benefit without cognitive adverse effects of ECT.
Key learning objectives include:

Review the background and rationale for studying MST and ECT in the treatment of depression.
Understand the methodology and design of the CREST and CORRECT-BD trials.
Evaluate the efficacy, safety, tolerability, and clinical implications of MST as a potential treatment for TRD.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, July 10, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - July 7, 2026 at 8:00pm ET | 5:00pm PT
UK- July 8, 2026 at 1:00am BST
Australia- July 8, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Daniel M. Blumberger, MD, MSc, FRCPC, FCTMSS

Dr. Blumberger is a Senior Scientist in the Campbell Family Mental Health Research Institute at Centre for Addiction and Mental Health and a subspecialist in geriatric psychiatry. He is the Temerty Chair in Therapeutic Brain Intervention and the Scientific Director of the Temerty Centre for Therapeutic Brain Intervention. He is the Chief of the General Adult Psychiatry and Health Systems Division at CAMH and is a Professor in the Department of Psychiatry at the University of Toronto. He is the Provincial Clinical Lead for Neurostimulation Procedure for Ontario Health.
His primary area of research focuses on clinical intervention trials of neurostimulation and other novel treatments for depression across the lifespan.
He is the principal or co-investigator on multiple clinical trials using different interventional psychiatry modalities including: psilocybin assisted psychotherapy, IV ketamine, electroconvulsive therapy (ECT), magnetic seizure therapy (MST), repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS).

Autonomic Outflow as a Rapid Read-Out of Brain Stimulation Targets for Anxious Arousal
2026-08-04 20:00 - 21:00 UTC
> >Register Now <<
Speaker: Ryan Webler, MD
Autonomic hyperactivation is a core feature of anxiety-related disorders that is inadequately addressed by current treatment approaches. Localizing autonomic
arousal to a specific brain circuit could inform the development of new treatments.
Here, Dr. Webler presents causal circuit mapping findings showing that focal brain stimulation sites that rapidly modify autonomic arousal map to a convergent brain circuit across stimulation modalities (TMS, DBS, LIFU). In additional independent datasets, modulation of this circuit predicts sustained changes in anxiety-related autonomic hyperactivation. These findings: (1) implicate the autonomic arousal circuit as a potential brain stimulation target for autonomic hyperactivation, and (2) suggest that rapid autonomic arousal changes could potentially serve as a biomarker of sustained autonomic arousal changes.
Key learning objectives include:

Describe how autonomic hyperactivation to anxiogenic stimuli contributes to clinical anxiety, and why it is inadequately addressed by current treatments.
Explain how focal brain stimulation (e.g., TMS, DBS, LIFU) can rapidly modulate autonomic outflow, and how this outflow maps onto a convergent brain circuit for sympathetic arousal.
Evaluate the evidence that the autonomic arousal circuit predicts sustained changes in anxious arousal and identify its potential as a therapeutic target.

One CME credit is available. CE Language
Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, August 7, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - August 4, 2026 at 8:00pm ET | 5:00pm PT
UK- August 5, 2026 at 1:00am BST
Australia- August 5, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Ryan Webler, MD
Dr. Ryan Webler is a postdoctoral research fellow at Harvard Medical School where he uses causal circuit mapping to develop better brain stimulation treatments for anxiety-related disorders. Complementing his research agenda, he is also a postdoctoral clinical fellow at Boston Precision Neurotherapeutics where he implements evidence-based psychotherapeutic protocols to bolster TMS gains.

Transcranial Magnetic Stimulation's Journal Club
2026-08-18 12:00 - 17:00 UTC | Zoom
Transcranial Magnetic Stimulation is the Society's open-access journal and is the first premier journal dedicated to clinical and foundational studies of TMS.
Members of the Research Committee host a quarterly journal club meeting during which published authors of Transcranial Magnetic Stimulation present their research and answer questions from attendees. Participation in the journal club—and access to the journal—is free and open to both Society members and non-members.
Date/Time:

USA - Tuesday, August 18, 2026 at 12:00pm ET
UK - Wednesday, August 18, 2026 at 5pm GMT
Australia - Thursday, August 19, 2026 at 4am AEDT

Zoom Link:
https://us02web.zoom.us/j/81925772026?pwd=[REDACTED]
Webinar ID: 819 2577 2026
Passcode: [REDACTED]
Can't make this date and time? The recording will be available on the CTMSS website.

EEG-guided TMS: the State of the Evidence
2026-09-01 20:00 - 21:00 (America/New_York)
> >Register Now <<
Speaker: Andrew F. Leuchter, MD
Treatments for Major Depressive Disorder (MDD) act at different hierarchical levels of biological complexity, ranging from the individual synapse to the brain as a whole. Evidence suggests that modulation of synchronized electrical activity in brain networks may integrate these different levels of complexity, and may be central to the mechanism of action of repetitive Transcranial Magnetic Stimulation (rTMS). Several lines of research indicate that electroencephalogram (EEG) recording during rTMS can help elucidate the mechanism of action of rTMS treatment. There is emerging evidence that EEG also may be useful in guiding selection of EEG treatment parameters. This presentation will review data on whether EEG guidance of rTMS treatment can improve treatment outcomes for MDD or other neuropsychiatric disorders.
Key learning objectives include:

Discuss the possible role of biomarkers to guide TMS treatment
Understand the rationale for EEG measurement of the effects of EEG treatment
Examine evidence supporting the use of EEG to guide clinical treatment

Take advantage of our live Q&A session at the conclusion of the webinar.
*Registered attendees will receive access to the on-demand video recording by Friday, September 4, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.
When:
USA - Sept 1, 2026 at 8:00pm ET | 5:00pm PT
UK- Sept 2, 2026 at 1:00am BST
Australia- Sept 2, 2026 at 10:00am AEST
Cost:
Member: $25
Trainee Member: FREE
Non-Member: $50
> >Register Now <<
About the Speaker

Andrew F. Leuchter, MD
Andrew F. Leuchter, MD, is a Distinguished Professor of Psychiatry and Director of the Neuromodulation Division at UCLA. An expert on the treatment of mood disorders, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. This is one of the largest academic TMS program in the country and treats patients with depression, OCD, pain, tinnitus, and other neuropsychiatric illness. His research aims to develop novel treatment strategies and predict which treatments are most likely to benefit individual patients.​
Dr. Leuchter has authored over 200 scientific articles on topics including neuromodulation for the treatment of depression, EEG biomarkers to guide treatment of neuropsychiatric illness, and theories of antidepressant action. He teaches internationally on TMS and other neuromodulation methods.

Pain Academy San Diego
2026-10-15

PULSES Providence
2026-10-23 - 2026-10-25
Course Overview
This in-depth training course offers a Certificate of Completion and features lectures and over 3 hours of hands-on training delivered by Clinical TMS Society renowned clinicians, engineers, and researchers, along with special guests. Attendees will receive current, historical, and practical knowledge for treating patients with TMS based on the best available evidence.
The Program Includes:

A review of the clinical studies that serve as the foundation for treatment of TMS for depression, as well as clinically applicable research and current important studies.
Four lectures on the practical administration of TMS for patients, including practice setup to patient dosing, scheduling, and management.
A review of protocols for TMS: high frequency, theta-burst, low frequency, bilateral, alternative brain targets, rescue treatment, and maintenance treatment.
A revised lecture on TMS risks and their prevention and management, including seizure protocol review.
Hands-on training on coil location placement & motor threshold determination with multiple TMS devices.
A review of promising indications beyond depression, including, obsessive compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, anxiety, and pain.
An extended Q&A Panel with all PULSES faculty and special guests.

Register
